Bottom Line:
There was a comparable, highly significant decrease in TMI with amlodipine and atorvastatin, but no additional benefit for the combination.Adverse events were comparable among groups.Atorvastatin was as potent an anti-ischaemic agent as amlodipine.

EHQ133F4: Twenty-four-hour circadian patterns during ambulatory electrocardiographic monitoring for the three treatment groups.

Mentions:
At baseline, the circadian pattern for TMI was observed in all three arms. By Week 18, there was a marked reduction in ischaemic events over 24 h in all three arms (P < 0.001 vs. baseline for all three cohorts), with little additional reductions recorded between Weeks 18 and 26 (Figure 4).

EHQ133F4: Twenty-four-hour circadian patterns during ambulatory electrocardiographic monitoring for the three treatment groups.

Mentions:
At baseline, the circadian pattern for TMI was observed in all three arms. By Week 18, there was a marked reduction in ischaemic events over 24 h in all three arms (P < 0.001 vs. baseline for all three cohorts), with little additional reductions recorded between Weeks 18 and 26 (Figure 4).

Bottom Line:
There was a comparable, highly significant decrease in TMI with amlodipine and atorvastatin, but no additional benefit for the combination.Adverse events were comparable among groups.Atorvastatin was as potent an anti-ischaemic agent as amlodipine.